Inhibrx Biosciences director Jon Kayyem buys $500,000 in common stock
Inhibrx Biosciences director Jon Kayyem acquired 5,000 shares of the company's common stock for $500,000 on September 23, 2026. The stock was trading around $100 at the time of the purchase, following a substantial 247% gain over the previous year. According to InvestingPro analysis, the stock may be overvalued based on its Fair Value estimate. After this transaction, Kayyem's indirect beneficial ownership in Inhibrx Biosciences common stock is spread across multiple trusts and custodial accounts.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
